NEWCORONAVIRUS INFECTIONANDPULMONARYTUBERCULOSIS: CLINICAL CASES

At the end of 2019, an outbreak of a new coronavirus infection, SARS-CoV-2, emerged in the People’s Republic of China with the epicenter in the city of Wuhan, Hubei Province. On February 11, 2020, the World Health Organization determined the official name of the disease caused by the new coronavirus – COVID-19, and on March 11, 2020, announced the beginning of a pandemic caused by the SARS-CoV-2 infection. COVID-19 is a “young disease”, which determines the importance of studying the influence of chronic comorbid pathology on the risk of infection with SARS-CoV-2, the severity of the course and the likelihood of developing an unfavorable outcome of the disease. Accumulated data identify several risk groups for severe COVID-19. First of all, this applies to patients with concomitant chronic pathologies: diabetes, cardiovascular diseases, obesity, and others [5, 15]. Coinfections affecting the respiratory tract pose clinical dilemmas as well as diagnostic and therapeutic challenges. This article presents clinical cases of the course of a combination of COVID-19 infection and pulmonary tuberculosis. The new coronavirus infection was more severe in a female patient with newly diagnosed tuberculosis than in a female patient with a chronic tuberculosis process, which confirms a different influence of the pathological processes on each other.